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NA Structural Variants
s Genetic Risk Factors
or the Long QT Syndrome*
tephen S. Rich, PHD,†‡ Ira M. Hall, PHD‡§
harlottesville, Virginia
he long QT syndrome (LQTS) is a rare, inborn heart
ondition in which delayed repolarization of the heart
ollowing a heartbeat increases the risk of episodes of
orsades de pointes (1,2). These episodes may be provoked
y numerous stimuli and, in extreme cases, may lead to
udden death due to ventricular fibrillation (3,4).
See page 40
The study by Barc et al. (5) in this issue of the Journal
llustrates the promise of using genetic information for
isease prediction and prevention. Determining whether
eoxyribonucleic acid (DNA) sequence polymorphisms or
NA structural variants are associated with subclinical
arkers (e.g., electrocardiogram [ECG] pattern) or clinical
isk of syncope or cardiac arrest in otherwise healthy
ndividuals would be of great importance. Barc et al. (5)
rovide evidence that DNA deletions ranging in size from
10 to 650 kb can lead to both subclinical and clinical
bnormalities; however, this direct link between DNA
tructural variants and clinical phenotype may be largely
imited to rare (and relatively large) genetic rearrangements.
ommon structural variants will likely have more subtle
ffects and be more difficult to interpret.
LQTS has been shown to aggregate in families by careful
linical observation and longitudinal studies (6). In family
tudies, the LQTS inheritance pattern has been shown to be
onsistent with either an autosomal dominant (transmitted
rom parent to child, requiring 1 variant allele) or an
utosomal recessive (appearance in families with carrier
arents, requiring 2 variant alleles) locus. These mutations
end to prolong the duration of the ventricular action
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Public Health Sciences, University of Virginia, Char-
ottesville, Virginia; ‡Center for Public Health Genomics, University of Virginia,
harlottesville, Virginia; and the §Department of Biochemistry and Molecularm
enetics, University of Virginia, Charlottesville, Virginia. The authors have reported
hat they have no relationships to disclose.otential, lengthening the QT interval, and corresponding
o the pattern seen on the ECG (1,2).
A number of genes have been identified in which muta-
ions lead to LQTS, with no single mutation in a gene
esponsible for a significant number of cases. This indicates
hat there may be many rare, as-yet-unidentified functional
ariants within LQTS susceptibility genes. For example,
QT1 (the most common type of LQTS, between 30% and
5% of all cases) is caused by loss-of-function mutations in
he KCNQ1 gene on chromosome 11p15.5 that encodes the
lpha subunit of the slow delayed rectifier potassium chan-
el (7). These mutations often cause LQTS by reducing the
mount of repolarizing current, leading to an increase in the
ction potential duration, and tend to be the most common
et least severe. LQT2 (the second most common form of
QTS, between 25% and 30% of all cases) is caused by
utations in the KCNH2 (HERG) gene on chromosome
q36.1 that encodes for the pore-forming alpha subunit of
he rapid delayed rectifier potassium channel (8). The third
ost common gene involved in LQTS is SCN5A (LQT3),
he alpha subunit of the voltage-gated type V sodium
hannel located on chromosome 3p21. Whereas LQT1,
QT2, and LQT3 account for over 90% of all mutations
dentified in LQTS cases, there are 9 additional LQTS
enes that can cause altered ion-channel currents, and more
han 600 different mutations have been identified among
he 12 known genes (9). For many patients with LQTS,
owever, the underlying cause remains to be determined.
In their study, Barc et al. (5) hypothesized that the
emaining, unknown genetic forms of LQTS could be, in
art, determined by DNA structural variants (specifically
opy number variants, or CNVs) rather than DNA se-
uence variants (such as single nucleotide polymorphisms,
r SNPs). Earlier reports suggested that large deletions (10)
r duplications (11,12) could lead to LQTS. In order to test
his hypothesis, Barc et al. (5) investigated the role of rare
eletions and duplications in LQT1 (KCNQ1) and LQT2
KCNH2) in 93 cases with LQTS for which sequence
ariants in the exons and intron/exon boundaries for LQT1,
QT2, and LQT3 could not be identified by either dena-
uring high-performance liquid chromatography (dHPLC)
r Sanger sequencing.
The value of genetics in identifying the molecular defects
esponsible for rare, single-gene (Mendelian) disorders is
eyond dispute. In many examples (such as neonatal diabe-
es), the molecular diagnosis has led to both novel treat-
ents and improved diagnosis/prediction. Even within the
endelian diseases, there can be multiple sites of sequence
ariation that lead to the clinical outcome, with different
ites often resulting in variation in disease severity. The
umber of single-gene disorders account for a small pro-
ortion of the overall burden of disease with a genetic
omponent. In the case of LQTS, 3 distinct genes account
or 90% of the mutations identified in patients, thereby
aking each defined as a “single gene” disorder. Nonethe-
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December 28, 2010/January 4, 2011:48–50 CNVs in Long QT Syndromeess, there are “missing” genetic etiologies that lead to
QTS in a substantial proportion (10%) of patients.
In the paper by Barc et al. (5), the diagnosis of LQTS was
ased upon the ECG (heart rate–corrected QT [QTc]
uration and T-wave morphology) as well as clinical and
amily history, with duplicate ECG readings and full med-
cal examination to exclude other forms of QT prolongation
nd misclassification in the genetic analysis. Multiplex
igation-dependent Probe Amplification (MLPA) was per-
ormed to screen for CNVs affecting KCNQ1, KCNH2, and
CN5A, and genome-wide array comparative genomic hy-
ridization (CGH) was used to map CNVs identified by
LPA to higher resolution. In the 93 cases, 1 heterozygote
eletion in LQT1 (KCNQ1) and 2 heterozygote deletions in
QT2 (KCNH2) were observed, with no structural varia-
ion identified in SCN5A.
Identification of deletions in 3 of 93 cases (probands) led
o recruitment of family members for subsequent evaluation
or evidence of transmission of the deletions and correlation
ith LQTS-related phenotype. One proband (heterozygote
arrier, Family 1) had a 650-kb deletion that extended from
xon 4 through the 3= region in KCNH2. This CNV was
resent in 6 family members with ECG findings consistent
ith LQTS (based upon QTc interval) but who were
symptomatic at time of examination. The CNV was absent
n 9 family members, all of whom had normal ECG reports.
n this family, the presence of the CNV (deletion) is highly
orrelated with subclinical (ECG) phenotype, although
linical evidence remains to be determined.
A second proband (Family 2) also had a heterozygote
eletion of KCNH2, this time of size 145 kb. Four family
embers (mother, brother, 2 sons) were examined for
vidence of transmission of the deletion and phenotypic
orrelates of LQTS. Both the mother and the brother
arried the deletion; however, the mother had prolongation
f the QTc interval, whereas the brother had a normal
CG. The third proband (Family 3) had a small, impre-
isely mapped deletion (2 to 14 kb) affecting exons 7 to 8 of
CNQ1. Three relatives (father, mother, and sister) were
xamined, with only the father having evidence of the
eletion but also a borderline LTQS phenotype (suggestive
-wave pattern and QTc of 438 ms). Both the mother and
ister failed to carry the deletion and had normal ECG
eadings. In these 2 families, the presence of the deletion is
ot highly predictive of either subclinical (ECG) or clinical
henotypes.
Recent studies have demonstrated that CNV in the
uman genome is extensive and could play an important
ole in susceptibility to disease, particularly in autism (13)
nd schizophrenia (14). A region on chromosome 16p11.2
as unique in that it had multiple de novo CNVs yet no
vidence of inherited risk for autism, and a 593-kb deletion
dentified 2 candidate genes: ATP10A and GABRB3. Dele-
ions and duplications larger than 100 kb also have been
dentified from 150 individuals with schizophrenia and 268
ncestry-matched controls (15). Novel deletions and dupli- uations of genes were present in 5% of controls compared
ith 15% of all cases (and in 20% of young-onset cases,
hose thought to be more severely affected). Mutations in
ases disrupted genes disproportionately from pathways
ontrolling neurodevelopment, including neuregulin, ERK/
APK signaling, synaptic long-term potentiation, axonal
uidance, and glutamate receptor pathways. Thus, just as for
equence variation in candidate genes, analysis of structural
ariation can lead to biologically meaningful insights on
isease mechanism.
Despite the considerable promise of structural variation
eing associated with disease, CNVs are not straightforward
o genotype, and current methods to examine structural
ariation genome-wide (rather than in specific gene regions)
re rapidly evolving (16,17). Structural variation (which
ncludes duplications, deletions, and balanced rearrange-
ents) has been shown to exist of all sizes and classes, and
mall CNVs have been under-represented due to the tech-
ical difficulties inherent in discovering and genotyping
hese variants. As noted by Barc et al. (5), the CNV sizes
etected are variable (10 to 650 kb) with detectable effects
n ECG (but not necessarily on clinical outcome). This
esult is consistent with the recent prediction that, for
omplex phenotypes, the contribution to disease suscepti-
ility by CNVs may be small (17). This prediction is
upported by the findings of the Wellcome Trust Case
ontrol Consortium (18) who, in a study of 8 common
iseases, identified just 3 common CNVs associated with
isease, all of which had been previously identified by
NP-based mapping.
The significance of CNVs on risk of LQTS remains
nclear. Barc et al. (5) suggest that CNV typing in KCNQ1
nd KCNH2 be considered part of a “routine work up of
QTS in the absence of point mutations in the 3 major
QTS genes.” This recommendation should be considered
n the context of other (unknown) variants and the limita-
ions of the current study. First, there is clear rationale for
creening LQT1, LQT2, and LQT3 for DNA sequence
ariants contributing to LQTS, as these 3 genes account for
90% of the patients identified with risk variants. The
anner in which the screening occurs (now and in the
uture) provides a foundation for any recommendation.
ather than focusing purely on exons or intron/exon bound-
ries by dHPLC or Sanger sequencing, other approaches
hould be employed. Targeted sequencing has become
ommon and is rapidly decreasing in cost, so capturing the
ntire gene and screening the complete sequence could
dentify both DNA and structural variants. This transition
rom inspection of “pieces” of genes to “complete” genes
ould provide near-complete genetic information. Of ad-
itional interest is the identification of all genetic contrib-
tors to LQTS. As noted in the previous text (17), one can
ot only survey the entire genome for CNVs, but also
haracterize those CNVs that are of much smaller size. This
urvey could assist in the detection of novel genes contrib-
ting to the residual LQTS genetic risk. As whole genome
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CNVs in Long QT Syndrome December 28, 2010/January 4, 2011:48–50pproaches become available, the cost and utility of DNA
equencing to detect both sequence and structural variation
ontributing to LQTS becomes feasible.
The practice of using genetic information to improve risk
rediction is progressing at a rapid pace. In order to
emonstrate the utility of genetic information for predic-
ion, the genetic risk factors should be required to improve
pon traditional risk factors. To date, the improvement of
enetic risk for common, complex disease has been subtle.
n the LQTS, the disease is relatively uncommon, and the
enetic information correlates highly with risk and, in some
ases, efficacy of treatment or intervention. In the Barc et al.
5) family collection, there is an opportunity to practice
personalized medicine” as members of 3 families have been
dentified as carriers of a CNV that (at least in 1 family)
racks with a LQTS ECG pattern. The transition from
iscovery of genetic variation to clinical practice, especially
n asymptomatic individuals (based upon QT interval or
-wave morphology) is a topic with significant medical
mplications.
In summary, Barc et al. (5) have studied 93 cases of
QTS that lack DNA sequence variants that could be
redictive of the disease by standard genotyping methods.
n 3 cases, a heterozygote deletion (forming a copy number
ariant, CNV), in LQT1 and LQT2 was identified. In all 3
amilies, the CNV was transmitted to other family mem-
ers; however, there were differences between the presence
f CNV and the LQTS ECG pattern. This study raises new
uestions regarding the biological mechanisms of LQTS
nd the relationship between disrupted gene structure and
unction. Future studies examining the role of deleted or
utated genetic material on the function of ion channels are
arranted. These studies may lead to novel insights on the
anner in which the channels are regulated and provide the
eld with additional, predictive biomarkers that can be used
ith the ECG as predictors of cardiac arrest and sudden
eath.
eprint requests and correspondence: Dr. Stephen S. Rich,
niversity of Virginia, Center for Public Health Genomics, 6111
est Complex, P.O. Box 800717, Charlottesville, Virginia 22908.-mail: ssr4n@virginia.edu.
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